Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Canine Atopic Dermatitis Market Expected To Grow In Terms Of Size?

The market size for canine atopic dermatitis has seen swift expansion in the past few years. There is an anticipated growth from $2.49 billion in 2024 to $2.76 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.6%. This surge during the historic phase can be credited to factors such as the escalating number of pet owners, heightened awareness regarding pet health, a rising incidence of allergy-related conditions in dogs, an increase in spending on veterinary healthcare, and a wider availability of pet insurance.

The market size for canine atopic dermatitis is predicted to witness quick expansion in the following years. It is projected to escalate to $4.09 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%. This projected growth during the forecast period could be attributed to factors like the rising preference for telemedicine in veterinary care, an increase in demand for tailored pet solutions, advancements in veterinary research and development, the growing trend of treating pets like a part of the family, and increased incorporation of artificial intelligence into veterinary diagnostics. Predicted trends for the forecast period encompass the evolution of monoclonal antibody treatments, the implementation of artificial intelligence in veterinary diagnostics, the integration of telemedicine for dermatology, the usage of wearable gadgets for symptom tracking, advanced allergen-specific immunotherapy, and mobile applications for monitoring treatment.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

What Are The Primary Factors Supporting The Canine Atopic Dermatitis Market Expansion?

An escalation in the incidence of skin allergies among dogs is anticipated to stimulate the expansion of the canine atopic dermatitis market. Skin allergies in dogs are unusual immunological reactions to allergens such as pollen, food or bites from fleas, leading to symptoms like itching, inflammation, and skin irritation. The increment in skin allergy cases in dogs is partially due to increased exposure to environmental pollutants and allergens, producing amplified immune responses and skin irritation. Therapies for canine atopic dermatitis aid in the management of skin allergies in dogs by decreasing inflammation and itching and preventing secondary infections, thereby enhancing their comfort and skin health. As per data from the National Institutes of Health (NIH), a US governmental agency, in January 2024, a total of 7,915 dog owners, which accounts for 28.7%, indicated that their dogs had a history of skin conditions. The rate of reported skin problems rose consistently with age, beginning at 7% in puppies and growing to 37% in senior dogs. Hence, the surge in skin allergy cases in dogs is pushing the growth of the canine atopic dermatitis market. The increasing trend of pet ownership is expected to accelerate the canine atopic dermatitis market’s growth. Pet ownership implies owning and caring for a domestic animal, such as a dog, cat, bird, or another companion animal. The surge in pet ownership can be attributed to the growing trend of pets’ humanization, with animals being considered as family members, thus elevating the demand for companionship and emotional support. The treatment of canine atopic dermatitis is useful for pets as it alleviates chronic itching and inflammation, improves skin health, and enriches their overall comfort and quality of life. In April 2025, as per the American Pet Products Association (APPA), a trade association based in the US that supplies and produces pet products, 94 million US households (71%) owned a pet, an increase from 86.9 million US households (66%) owning a pet during 2023-2024. Therefore, the increment in pet ownership is propelling the growth of the canine atopic dermatitis market.

Which Segmentation Categories Are Highlighted In The Canine Atopic Dermatitis Market Analysis?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Market Trends Are Expected To Define The Future Of The Canine Atopic Dermatitis Market?

Leading corporations in the canine atopic dermatitis market are concentrating their efforts on securing regulatory approvals in order to increase the global reach and use of their therapies. Regulatory approvals are the official authorizations issued by government health departments that permit companies to distribute and sell their medical products after demonstrating their safety, efficacy, and quality through intensive testing. For example, Elanco Animal Health Inc., a pharmaceutical company from the US with a focus on animal health, was awarded US FDA approval for Zenrelia, a once-daily oral JAK inhibitor for dogs suffering from allergic and atopic dermatitis, in September 2024. The authorization of Zenrelia signifies a substantial progression in treating dogs with chronic, acute, or seasonal itch and inflammation, encapsulated in a single, once-daily tablet from the beginning. Zenrelia functions by identifying and inhibiting the itch source, disrupting the itch-scratch cycle. From the first dosage, Zenrelia provides noticeable improvements and lowers the chance of rebound itch, a frequent problem in numerous dogs treated with the rivaling JAK inhibitor.

Which Organizations Are At The Forefront Of The Canine Atopic Dermatitis Market?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., IDEXX Laboratories Inc., Royal Canin SAS, Ceva Santé Animale S.A., Boragen, Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Antech Diagnostics Inc., Vetoquinol S.A., Heska Corporation, Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Bioceltix S.A., Nextmune AB, OKAVA Pharmaceuticals Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Canine Atopic Dermatitis Market?

North America was the largest region in the canine atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

Browse Through More Reports Similar to the Global Canine Atopic Dermatitis Market 2025, By The Business Research Company

Dog Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Canine Arthritis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/canine-arthritis-treatment-global-market-report

Allergy Conjunctivitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/allergy-conjunctivitis-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model